LOS ANGELES, Calif., Aug. 29, 2022 (SEND2PRESS NEWSWIRE) — California firm, ProNova Partners, has been chosen to handle the sale of the patent and rights to an easily removable mesh sling based on the natural encapsulation around monofilament wires or its interconnected narrow and flat strips. This encapsulation allows its easy removability.
LOS ANGELES, Calif., Aug. 24, 2022 (SEND2PRESS NEWSWIRE) — ProNova Partners, an L.A. based Mergers and Acquisitions firm, has been selected to oversee investment in or the sale of a patented, groundbreaking ID and security technology. This technology involves iris recognition including in the outdoors under bright sunlight, plus world-leading iris recognition tech secured by crypto wallet.
LOS ANGELES, Calif., June 24, 2022 (SEND2PRESS NEWSWIRE) — ProNova Partners, a seventeen-year-old California based Mergers and Acquisitions firm, has been commissioned to assist in the sale of all rights to manufacture and sell a patented, painless, non-invasive, device to eliminate hemorrhoids. Use of the device requires no anesthesia, is conducted in under 2 minutes, and can be performed in any medical setting: a doctor’s office, a surgery center, an endo suite, or a hospital.
LOS ANGELES, Calif., June 2, 2022 (SEND2PRESS NEWSWIRE) — Southern California based Mergers and Acquisitions firm ProNova Partners has been commissioned to facilitate investment in or the sale of a patented, groundbreaking packaging technology. The technology facilitates a secure, traceable, and reusable end-to-end transport solution for expensive medical therapies and products that rely on the cold chain.
LOS ANGELES, Calif., June 2, 2022 (SEND2PRESS NEWSWIRE) — Seventeen-year-old ProNova Partners has been contracted to facilitate the expansion of an Artificial Intelligence Radiology Imaging and emerging Medical Technology Venture Capital Investment Group.
LOS ANGELES, Calif., May 18, 2022 (SEND2PRESS NEWSWIRE) — ProNova Partners, a Los Angeles based, 25-year-old Mergers and Acquisitions (M&A) firm has announced their commission to facilitate the sale of a new, patented device to lower mortality and other risks in specific, major heart surgery procedures.
